Telehealth ADHD Prescribing: What PMHNPs Can Do

You spent years in medical school, residency, and probably a fellowship. You can diagnose complex psychiatric conditions, manage polypharmacy in treatment-resistant cases, and navigate the nuances of psychopharmacology. But right now, you’re Googling whether you can legally prescribe Adderall through a video call.

Welcome to the absurdity of 2026 healthcare regulation.

The short answer: Yes, psychiatrists can prescribe ADHD medications via telehealth right now — but you’re operating under temporary federal rules that could change, and state laws add another layer of complexity. If you’re considering telehealth ADHD practice (or already doing it), you need to understand both the current landscape and what’s coming.

Let’s cut through the regulatory fog.

The Federal Telehealth Prescribing Situation (As of February 2026)

Here’s what actually matters for your practice today:

The Ryan Haight Act (2008) normally requires an in-person medical evaluation before prescribing Schedule II controlled substances like Adderall, Vyvanse, or Ritalin. That’s the baseline federal law.

During COVID, the DEA waived this requirement for mental health treatment. You could start a new ADHD patient on stimulants entirely via video visit. That flexibility has been extended multiple times — most recently through December 31, 2025 (www.axios.com).

As of February 2026, we’re in limbo. The latest extension pushed the decision into 2025, and while there’s bipartisan support for making telehealth prescribing permanent for mental health, no permanent rule has been finalized (www.axios.com).

What this means for your practice:

• You can currently prescribe stimulants to new telehealth ADHD patients without an in-person visit
• Document thoroughly — conduct the same comprehensive evaluation you would in-person
• Have a backup plan: if the waiver expires without replacement, you may need partnerships with local clinics for in-person initial exams
• Stay subscribed to DEA updates (or join a platform that monitors this for you)

The regulatory uncertainty is frustrating, but the demand for your services isn’t going anywhere. Adult ADHD diagnoses surged during the pandemic and have stayed elevated. Stimulant prescriptions jumped significantly from 2020-2022, particularly for adults (apnews.com). Your expertise is needed — the question is just how much administrative burden you’ll tolerate.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-Specific Telehealth Rules: Where You Can Practice Freely

Federal law sets the floor, but states can add requirements. Some states explicitly welcomed psychiatric telehealth prescribing; others remain silent and defer to federal rules.

Florida: Explicitly Permits Telehealth ADHD Prescribing

Florida went out of its way to make this clear. State law allows prescribing Schedule II controlled substances via telehealth specifically for psychiatric disorders (www.flsenate.gov). ADHD qualifies.

If you’re Florida-licensed, you can conduct a video evaluation, diagnose ADHD, and e-prescribe Adderall to a patient sitting in their home in Tampa — all legally, as long as you meet standard of care requirements. Florida carved out this exception because they recognized mental health treatment is different from pain management (which has tighter telehealth restrictions).

Florida requirements:

• Must be fully licensed in Florida (not just telehealth registration)
• Must check the state PDMP (EFORCSE) before prescribing controlled substances
• Must use e-prescribing (paper scripts for stimulants are essentially prohibited)
• Standard psychiatric documentation applies

Texas: Video Required, But Otherwise Open for Psychiatry

Texas allows telehealth prescribing of controlled substances for mental health conditions, but with one key requirement: synchronous audio-visual communication — meaning video, not just phone (www.cchpca.org).

Texas explicitly prohibits telehealth prescribing of controlled substances for chronic pain management, but ADHD isn’t chronic pain. Psychiatrists treating ADHD via telehealth in Texas are fine as long as they use video and conduct a proper evaluation.

Interestingly, Texas doesn’t require checking the PDMP for stimulants (the mandate applies to opioids, benzos, and a few others), but it’s still best practice.

One critical limitation in Texas: This applies to physicians only. We’ll get to the NP situation in a moment, but if you’re an MD/DO, you have full authority here.

California, New York, Pennsylvania, Illinois: Follow Federal Rules

These states don’t impose additional telehealth-specific restrictions on psychiatric prescribing beyond what federal law requires. If the DEA says you can do it, you can do it in these states.

California has strong telehealth parity laws and mandates e-prescribing for controlled substances (since 2022), so you’ll need an EPCS-compliant platform.

New York requires checking the state Prescription Drug Monitoring Program (I-STOP registry) before every controlled substance prescription — this is non-negotiable and applies to stimulants. It’s a workflow step, not a barrier, but skip it and you risk disciplinary action.

Pennsylvania and Illinois have embraced telehealth for mental health with insurance parity. No special hoops beyond federal compliance and standard PDMP checks.

In all these states, as long as you’re licensed where the patient is located, you can provide telehealth ADHD care including prescribing stimulants (under current federal allowances).

Psychiatrist vs PMHNP Prescribing: Why Your MD Matters More Than Ever

Here’s where scope of practice gets messy — and why platforms desperately need psychiatrists.

As a psychiatrist (MD/DO), you have unrestricted prescribing authority in every state. No supervision, no collaborative agreements, no quantity limits on Schedule II medications. You can prescribe a 30-day supply of Adderall to a new patient after a thorough telehealth evaluation, and no state law stops you.

PMHNPs face a patchwork of restrictions:

States Where NPs Can Prescribe ADHD Meds Independently (After Experience)

• New York: After 3,600 supervised hours (~2 years), NPs can practice fully independently including prescribing stimulants (rxagent.co)
• Illinois: After 4,000 hours + additional training, NPs can obtain Full Practice Authority and prescribe stimulants without physician oversight (rxagent.co)
• California: Transitioning to independence — experienced NPs (≥3 years/4,600 hours) can apply for independent practice status (104 NP) and prescribe Schedule II meds after completing required pharmacology courses (rxagent.co)

States Where NPs Need Physician Collaboration (But Can Still Prescribe Stimulants)

• Pennsylvania: NPs require a collaborative agreement and face limits — only 72 hours of Schedule II on an initial prescription, then 30-day supplies after physician involvement (rxagent.co)
• Florida: NPs need a psychiatrist supervisor. There’s normally a 7-day limit on Schedule II prescriptions, BUT psychiatric nurses (PMHNPs working under a psychiatrist’s protocol) are exempt and can prescribe 30-day supplies for ADHD (www.leg.state.fl.us)

States Where NPs Basically Can’t Prescribe ADHD Stimulants

• Texas: NPs cannot prescribe Schedule II controlled substances for outpatient use except in hospitals, hospice, or emergency settings (rxagent.co). For routine ADHD management, only physicians can write the prescriptions.

What this means for telehealth platforms:

In restrictive states like Texas and Florida, psychiatrists are essential — you’re not just another provider type, you’re the only provider type who can handle stimulant prescribing independently. In states moving toward NP autonomy, you’re still valuable for complex cases, supervision roles, and handling patients who need the full scope of psychiatric care beyond medication.

The economic reality: platforms need to recruit psychiatrists to operate in all 50 states. They need NPs to scale efficiently in permissive states. If you’re an MD, you have leverage.

The Clinical Reality: What Telehealth ADHD Care Actually Looks Like

Forget the regulatory anxiety for a moment. Can you actually provide good ADHD care via video?

Yes, and in many ways it’s better than in-person for this population.

The Initial Evaluation

A comprehensive ADHD assessment via telehealth typically includes:

• Clinical interview covering childhood symptoms, current functioning, and differential diagnosis (you’re ruling out anxiety, bipolar, substance use, etc.)
• Standardized rating scales (ASRS for adults, Vanderbilt or Conners for kids) — easily administered via patient portal before the visit
• Collateral information when possible (old report cards for adults, teacher input for kids, partner observations)
• Mental status exam focusing on attention, impulse control, and mood — all observable via video
• Screening for contraindications (cardiac history, substance use, psychosis)

You don’t need to check blood pressure yourself during a video visit — you can ask patients to get vitals at a pharmacy or with a home cuff and report them. Most ADHD patients don’t need routine EKGs unless they have cardiac risk factors (then coordinate with their PCP or local urgent care).

The evaluation takes 45-60 minutes. You bill 90792 (psychiatric diagnostic evaluation with medical services) and get reimbursed around $190-200 from Medicare, often more from commercial insurance (therathink.com).

Ongoing Medication Management

Follow-ups are typically monthly (since stimulants are Schedule II, no refills allowed — each month is a new prescription). These visits are brief: 10-15 minutes to assess response, side effects, dose adjustments.

You’re billing 99213 (15-min established patient visit, ~$90 Medicare, $100-130 commercial) or 99214 if the visit is more complex (25 min, ~$125 Medicare, $140-180 commercial) (therathink.com).

The telehealth advantage: Patients don’t miss work for a 15-minute med check. No-show rates drop. You can see patients across your entire state (or multiple states if you’re multi-licensed) without geographic limitations.

The Medication Shortage Problem

Here’s the frustrating part that has nothing to do with telehealth: ADHD medications have been on backorder since late 2022 (www.axios.com).

Patients call their pharmacy and hear ‘We’re out of Adderall, try another pharmacy.’ You’re spending unpaid time helping them locate pharmacies with stock, switching to alternatives (Vyvanse, methylphenidate formulations, Qelbree), or dealing with insurance denials when you switch to a more expensive medication.

This isn’t a telehealth problem — it’s an ADHD prescriber problem in 2026, period. But it does mean you need workflows for:

• Sending prescriptions to multiple pharmacies if needed
• Having backup medication options ready
• Educating patients that the shortage isn’t their fault or yours

The DEA has increased production quotas for ADHD medications (www.axios.com), but distribution remains uneven.

Ensuring Compliance and Avoiding Regulatory Scrutiny

The elephant in the room: some telehealth companies got in serious trouble for overprescribing stimulants with minimal oversight. One major platform faced federal charges for inappropriately prescribing Schedule II controlled substances like Adderall via brief messaging without proper evaluation (capitol.texas.gov).

You don’t want to be associated with that.

Best practices to protect your license:

• Document comprehensively: Your notes should reflect a thorough diagnostic evaluation meeting DSM-5 criteria for ADHD
• Verify patient identity and location at every visit (for licensure compliance and medical record accuracy)
• Check the PDMP before prescribing (required in many states, best practice everywhere)
• Use e-prescribing with two-factor authentication (EPCS compliance)
• Schedule regular follow-ups — monthly for stimulants is standard, don’t just write ongoing scripts without contact
• Screen for misuse risk: Prior substance use disorder? Consider non-stimulant options first, or urine drug screens if indicated
• Coordinate with primary care when appropriate (especially for patients with medical comorbidities)

The standard of care via telehealth should be identical to in-person. Florida law explicitly states this (www.flsenate.gov), but it’s true everywhere.

Insurance Reimbursement: You’ll Actually Get Paid

One of the best developments in telehealth: parity is now nearly universal (behavehealth.com).

Almost every state has enacted telehealth parity laws or policies, meaning insurers pay the same rate for a virtual medication management visit as they would for an in-person visit. Medicare has extended telehealth coverage for mental health services (at non-facility rates, which is the higher reimbursement) through at least 2024, with strong indication this will continue (www.kiplinger.com).

Typical reimbursement for ADHD med management:

Source: Therathink 2026 Reimbursement Guide

As a psychiatrist, you’re reimbursed at the highest level for psychiatric services compared to other provider types (therathink.com). NPs in some states get 85% of physician rates when billing independently; therapists billing for psychotherapy get lower rates than medication management codes.

If you’re doing four 15-minute med checks per hour (realistic for established ADHD patients with stable medications), that’s approximately $360-520/hour gross from insurance depending on payer mix. Telehealth overhead is lower than office-based practice — no rent, minimal staff if you’re using a platform that handles scheduling and billing.

Medicaid Considerations

Medicaid rates are significantly lower (roughly $40-65 for a 15-minute visit in many states) (therathink.com), but Medicaid programs have broadly maintained telehealth coverage and parity post-pandemic. If you’re willing to see Medicaid patients, there’s enormous unmet need — particularly in states like Texas and Florida with large Medicaid populations and severe psychiatrist shortages.

Many telehealth platforms mix commercial insurance and cash-pay patients to optimize revenue. The economic model works.

State-by-State Market Opportunities

Where should you practice? Here’s what the data says about supply, demand, and regulations in our priority states:

Texas: Massive Demand, Restrictive NP Laws

The shortage: Texas has approximately 1 psychiatrist per 9,000 residents — one of the worst ratios in the country (www.healingpsychiatryflorida.com). Over 185 of Texas’s 254 counties are designated mental health shortage areas.

The opportunity: If you’re Texas-licensed, you can serve patients statewide via telehealth. Demand far exceeds supply. Because NPs cannot prescribe stimulants in outpatient settings, psychiatrists are the only option for ADHD medication management.

The catch: Some regulatory scrutiny on telehealth controlled substance prescribing (Texas legislature discussed abuses in 2023). Practice conservatively, document thoroughly.

Florida: Permissive Laws, High Growth

The shortage: About 1 psychiatrist per 8,577 residents (rank 42nd) (www.healingpsychiatryflorida.com). Distribution is uneven — Miami has providers, rural North Florida has almost none.

The opportunity: Florida explicitly allows telehealth ADHD prescribing for psychiatrists. Growing population, high demand from both youth and adults.

The model: Many Florida telehealth practices use a psychiatrist + PMHNP team structure (PMHNP can prescribe stimulants under psychiatrist supervision, exempted from the 7-day limit).

New York: Saturated in NYC, Gaps Upstate

The supply: Best psychiatrist-to-population ratio in the country — about 1:2,900 overall (www.healingpsychiatryflorida.com). But NYC skews this heavily; rural upstate counties have significant shortages.

The opportunity: Serve the entire state via telehealth. Upstate patients will find you. NYC patients want convenience. High insurance coverage rates mean steady reimbursement.

NP competition: New York NPs can practice independently after 2 years, so you’re competing with experienced PMHNPs. Differentiate with complex cases, diagnostic expertise, and comprehensive care.

California: Huge Market, Transitioning NP Rules

The supply: Moderate density overall (~1:5,000) but 7,800+ psychiatrists statewide means competition in metros, shortages in Central Valley and rural areas (www.healingpsychiatryflorida.com).

The opportunity: Largest state population means largest absolute number of ADHD patients. Tech-savvy population comfortable with telehealth. Strong insurance markets.

NP landscape: California is phasing in NP independence (AB 890), so by 2026 many experienced NPs are practicing independently. You’re competing, but there’s room for everyone given demand.

Pennsylvania & Illinois: Moderate Supply, Growing Telehealth Acceptance

Pennsylvania: ~1:4,600 ratio (better than average) but rural gaps. NPs require MD collaboration, so you’re needed for supervision or direct care. Strong parity laws support reimbursement.

Illinois: ~1:5,800 ratio. Chicago has many providers, downstate Illinois faces shortages. Illinois NPs can achieve full practice authority after 4,000 hours, creating a mixed landscape.

Both states: solid insurance coverage, established telehealth infrastructure, moderate competition.

The Real Economics: What Providers Actually Spend to Get Patients

Let’s talk about something most telehealth recruitment pitches gloss over: patient acquisition cost.

If you’re solo or joining a small practice, you might think about marketing yourself. Here’s the reality:

DIY marketing for a psychiatric practice typically costs $200-500+ per booked patient when you factor in:

• SEO agency fees ($2,000-5,000/month) for 6-12 months before you see traffic
• Google Ads ($15-40 per click for mental health keywords, with maybe 2-5% conversion to booked appointments)
• Directory listings (Psychology Today charges ~$30/month but you’re competing with hundreds of providers on the same page; Zocdoc charges $35-100+ per booking plus monthly subscription)
• Staff time to handle leads, screen calls, deal with no-shows from cold traffic
• Failed campaigns and testing periods before you find what works

Most solo psychiatrists don’t have the expertise or patience for 6-12 months of SEO investment with no guarantees.

This is where the economics of a platform like Klarity make sense:

Instead of spending $3,000-5,000/month on marketing with uncertain ROI, you pay only when a qualified patient books with you. Klarity uses a pay-per-appointment model for new patient leads (similar to Zocdoc’s booking fee structure, but without the monthly subscription).

The value proposition:

• Pre-qualified patients already matched to your specialty and availability (they want ADHD med management, they’re in your licensed state, they have insurance or are cash-pay)
• No upfront marketing spend — zero risk
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs, no IT headaches)
• Both insurance and cash-pay patient flow handled through one system
• You control your schedule — you decide availability and only pay when patients book

Compare this to spending months building an SEO presence or burning through a $4,000/month Google Ads budget where 90% of clicks bounce. Guaranteed ROI versus gambling on marketing channels.

This model works especially well for:

• Psychiatrists starting telehealth who don’t have an existing patient base
• Providers scaling beyond word-of-mouth referrals who need consistent new patient flow
• Multi-state licensed psychiatrists who want to maximize their licenses without running separate marketing campaigns in each state
• Providers in high-demand specialties (like ADHD) where patient volume, not marketing, should be the limiting factor

DIY marketing can eventually be cost-effective if you have the budget, expertise, and patience. But for most psychiatrists, especially those who’d rather spend time practicing medicine than optimizing Google Ads, a platform that handles patient acquisition removes the risk entirely.

Should You Join a Telehealth Platform for ADHD Care?

Here’s how to think about it:

Reasons to join a platform:

• You want consistent patient flow without handling your own marketing
• You’re multi-state licensed and want to maximize that investment
• You prefer focusing on clinical care, not running a business
• You want built-in compliance tools (PDMP integration, EPCS, documentation templates)
• You’re entering telehealth and don’t want to build infrastructure from scratch

Reasons to go independent:

• You already have a full practice and referral network
• You want to keep 100% of revenue (vs. platform fees)
• You enjoy the business side and want full control
• You’re willing to invest time and money in marketing and operations

What to evaluate in a telehealth platform:

• Licensing support: Will they help you get licensed in multiple states, or do you need to handle that yourself?
• Patient quality: Are these patients who actually need psychiatric care, or are you becoming a script mill?
• Clinical freedom: Can you decline patients who don’t meet criteria, or is there pressure to prescribe?
• Reimbursement model: Are you paid per visit? Salary? Revenue share? Is it transparent?
• Compliance infrastructure: PDMP checks, e-prescribing, documentation — is it built in or do you need separate tools?
• Malpractice coverage: Is it provided, or do you need your own policy that covers telehealth?

For ADHD specifically, make sure any platform has:

• Workflows for comprehensive diagnostic evaluation (not just a 10-minute symptom check)
• Medication shortage workarounds (ability to send scripts to multiple pharmacies)
• State-specific compliance for where you’re practicing
• Clear policies on controlled substance prescribing that align with your risk tolerance

Frequently Asked Questions

Can I prescribe ADHD medications to patients in other states via telehealth?

Only if you’re licensed in the state where the patient is located. You need an active, unrestricted medical license in the patient’s state to prescribe controlled substances to them. Some states participate in compacts (like the Interstate Medical Licensure Compact) that make it easier to get licensed in multiple states, but you still need the license before you see the patient.

Do I need a DEA registration in every state I practice?

No, you only need one DEA registration, but you must have a state medical license and controlled substance license (if required by that state) for each state where you’re prescribing. Your DEA number follows you across state lines as long as you’re properly licensed.

What happens if the federal telehealth waiver expires?

If the Ryan Haight Act in-person requirement returns without a replacement policy, you would need to either: (1) conduct an in-person initial exam before prescribing stimulants to a new patient, or (2) partner with local clinics/providers who could do the in-person visit, then you handle ongoing care via telehealth. Existing patients already on medication could likely continue with telehealth follow-ups. This would be disruptive but not practice-ending.

How do I handle patients who are clearly med-seeking?

The same way you would in-person: comprehensive evaluation, review PDMP, assess for genuine ADHD symptoms and functional impairment, consider non-stimulant trials first if you’re uncertain, and decline to prescribe if the clinical picture doesn’t support it. Document your reasoning. Telehealth platforms worth working with will support clinical judgment over patient satisfaction scores.

What’s the malpractice risk of telehealth ADHD prescribing?

Malpractice risk is primarily tied to whether you met the standard of care, not the modality of care. If you conduct a thorough evaluation, document appropriately, monitor for side effects and misuse, and follow clinical guidelines, your risk is no different than in-person practice. Make sure your malpractice insurance explicitly covers telehealth (most policies do now, but verify). The providers who got in trouble were doing cursory evaluations and prescribing with minimal oversight — don’t do that.

Can I prescribe stimulants via audio-only (phone) or does it have to be video?

Federal law doesn’t specify video vs audio for telehealth, but several states require video for controlled substances. Texas, for example, requires ‘synchronous audio-visual communication’ for prescribing controlled substances via telehealth. Best practice: use video for initial evaluations and stimulant initiations. Follow-ups might be okay by phone in some states, but check your state’s specific telehealth statutes.

What about prescribing for children — any additional requirements?

Pediatric ADHD prescribing via telehealth follows the same federal and state rules, with these additions: (1) You typically need parental consent (minor can’t consent alone), (2) Best practice includes collateral information from teachers/school (more important in kids than adults), (3) Some states require the minor be present on the video call along with the parent, not just the parent reporting symptoms. Growth monitoring (height/weight) is harder via telehealth for kids on stimulants — coordinate with the pediatrician or have parents report measurements regularly.

How do I compete with nurse practitioners in states where they can prescribe independently?

You don’t compete on price — compete on expertise. Position yourself for: complex cases (comorbid conditions, treatment-resistant ADHD, diagnostic uncertainty), comprehensive psychiatric evaluation (distinguishing ADHD from bipolar, anxiety, etc.), patients who specifically want a physician, and supervision/collaboration roles with NPs who need MD oversight. There’s enough demand that differentiation matters more than competition.

The Bottom Line: ADHD Telehealth Works, But Know the Rules

As a psychiatrist, you can absolutely build a thriving ADHD-focused telehealth practice in 2026. The clinical care is straightforward, reimbursement is solid, and demand is enormous.

The regulatory landscape is messy — temporary federal rules, state-by-state variations, pending legislation — but the current environment is permissive and likely to stay that way for mental health prescribing.

What you need:

• Active medical license(s) in the state(s) where you’re treating patients
• DEA registration and state controlled substance authority
• EPCS-compliant e-prescribing platform
• Workflow for PDMP checks
• Comprehensive evaluation and documentation process
• Awareness of your state’s specific telehealth and prescribing laws

What you should avoid:

• Cursory evaluations just to get scripts written
• Ignoring PDMP red flags
• Prescribing across state lines without proper licensure
• Assuming ‘telehealth’ means lower standards of care

The opportunity is real. Adult ADHD is underdiagnosed and undertreated. Medication shortages aside, patients who find a competent, accessible psychiatrist who can evaluate them thoroughly and manage their medication effectively will stay with you long-term.

If you’re considering joining a platform like Klarity: you bring clinical expertise and prescribing authority that’s in short supply. In states like Texas and Florida, you’re not just valuable — you’re essential. Use that leverage to find a partnership that respects your clinical judgment, pays fairly, and provides genuinely qualified patients.

The regulations will keep changing. The patient need won’t.

Ready to explore telehealth ADHD practice without the marketing headaches? Klarity Health connects psychiatrists with pre-qualified ADHD patients across multiple states, handling patient acquisition, credentialing support, and telehealth infrastructure so you can focus on clinical care. Learn more about joining Klarity’s provider network →

Sources & References

All regulatory and clinical information in this guide has been verified against current official sources as of February 2026:

Top 5 Key Citations:

1. DEA Telehealth Extension (Federal Policy): Drug Enforcement Administration and HHS extended COVID-era telehealth prescribing flexibilities for controlled substances through December 31, 2025 (third temporary extension). Source: Axios Health Policy, November 18, 2024. www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

2. Florida Telehealth Statute (State Law): Florida Statutes §456.47 explicitly permits telehealth prescribing of Schedule II controlled substances for treatment of psychiatric disorders. Source: Florida Senate Official Statutes, 2023 edition (current). www.flsenate.gov/Laws/Statutes/2023/456.47

3. Nurse Practitioner Prescribing Authority by State: Comprehensive state-by-state analysis of NP scope of practice and controlled substance prescribing authority, including specific limitations in Texas, Florida, Pennsylvania, and independence pathways in New York, Illinois, and California. Source: RxAgent Prescriptive Authority Guide, updated December 28, 2025. rxagent.co/blog/np-prescribing-authority

4. ADHD Prescription Surge During Pandemic: Prescriptions for ADHD treatments surged during the COVID-19 pandemic, with new prescriptions for stimulants used to treat ADHD increasing 13.9% in females and 6.2% in males ages 20-39 from 2020-2021, according to FDA researchers. Context on adult ADHD diagnosis increase and treatment access via telehealth. Source: Associated Press Health, January 10, 2024. apnews.com/article/228102e7d9a2e031b7b688d60faf208b

5. Psychiatrist Shortage by State (Workforce Data): State-by-state psychiatrist-to-population ratios showing Texas ranks 43rd (1:9,327 residents), Florida 42nd (1:9,318), New York 4th (1:2,900), California 11th (1:5,636), Pennsylvania 10th (1:4,586), and Illinois 18th (1:5,989). Source: Healing Psychiatry Florida shortage analysis, January 15, 2026 (data from HRSA). www.healingpsychiatryflorida.com/blogs/psychiatrist-shortage-by-state/

Additional Sources Cited:

• Florida Nurse Practice Act §464.012: APRN controlled substance prescribing

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the